Related Experiment Videos

Ampicillin-resistant Hemophilus influenzae type B septic arthritis in children

Clinical Pediatrics
|February 1, 1981
PubMed

Insights

Ampicillin-resistant Hemophilus influenzae type B caused septic arthritis in three young children. Intravenous chloramphenicol effectively treated all cases, suggesting its consideration for initial therapy in at-risk populations.

Area of Science:

  • Pediatric Infectious Diseases
  • Bacterial Pathogenesis
  • Antimicrobial Resistance

Background:

  • Septic arthritis in infants and young children poses significant clinical challenges.
  • Increasing antimicrobial resistance necessitates updated treatment guidelines.
  • Hemophilus influenzae type B was a common cause of invasive bacterial infections before widespread vaccination.

Observation:

  • Three pediatric cases of septic arthritis caused by ampicillin-resistant Hemophilus influenzae type B were observed between November 1978 and February 1979.
  • All patients were under 18 months of age and presented with positive blood and joint fluid cultures.
  • Serum testing confirmed Hemophilus influenzae type B, with minimum inhibitory concentrations for ampicillin at 6.25 µg/ml or higher.

Findings:

  • All three patients achieved uneventful recovery following treatment with intravenous chloramphenicol.
  • The study highlights the emergence of ampicillin resistance in Hemophilus influenzae type B isolates causing septic arthritis.
  • Chloramphenicol demonstrated efficacy against these resistant strains.

Implications:

  • Chloramphenicol should be considered in the initial management of septic arthritis in children under 18 months, particularly in regions with high ampicillin resistance rates.
  • This finding underscores the importance of monitoring antimicrobial resistance patterns for guiding pediatric infectious disease treatment.
  • Early and effective antimicrobial therapy is crucial for favorable outcomes in pediatric septic arthritis.

Related Concept Videos